« Return to News | CROs/Service Providers

Pharmaron Beefs Up Preclinical Offerings with Bridge Labs China Acquisition

Thursday, January 14, 2010 06:54 AM

Pharmaron Holdings acquired Bridge Laboratories China this week for an undisclosed sum, building on the contract research organization’s (CRO’s) existing presence in China.  

The acquisition gives Pharmaron access to an 84,000-square-foot preclinical laboratory with western Good Laboratory Practice-compliant preclinical toxicology service capabilities. According to Pharmaron, it is the first CRO in China to offer these services.

 “Pharmaron has built an exceptional team of scientists specialized in the areas of discovery and process chemistry, biology, DMPK, pharmacology and GMP manufacturing. The acquisition of Bridge Laboratories China enhances our drug R&D service capabilities by adding world-class expertise in western standard GLP-compliant toxicology and safety pharmacology to our diverse service portfolio,” said Pharmaron chairman and CEO Dr. Boliang Lou in a statement. “Pharmaron is now the first CRO in China to provide fully integrated drug discovery and development services, from discovery chemistry to IND filings.”

Bridge Laboratories China was a part of Maryland-based Bridge Laboratories until its U.S. assets were sold off in a management buyout last month.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.